139 related articles for article (PubMed ID: 10392320)
1. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance.
Kharasch ED; Jubert C; Senn T; Bowdle TA; Thummel KE
J Clin Pharmacol; 1999 Jul; 39(7):664-9. PubMed ID: 10392320
[TBL] [Abstract][Full Text] [Related]
2. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions.
Kharasch ED; Russell M; Mautz D; Thummel KE; Kunze KL; Bowdle A; Cox K
Anesthesiology; 1997 Jul; 87(1):36-50. PubMed ID: 9232132
[TBL] [Abstract][Full Text] [Related]
3. Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe.
Kharasch ED; Russell M; Garton K; Lentz G; Bowdle TA; Cox K
Anesthesiology; 1997 Jul; 87(1):26-35. PubMed ID: 9232131
[TBL] [Abstract][Full Text] [Related]
4. Menstrual cycle variability in midazolam pharmacokinetics.
Kharasch ED; Mautz D; Senn T; Lentz G; Cox K
J Clin Pharmacol; 1999 Mar; 39(3):275-80. PubMed ID: 10073327
[TBL] [Abstract][Full Text] [Related]
5. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans.
Phimmasone S; Kharasch ED
Clin Pharmacol Ther; 2001 Dec; 70(6):505-17. PubMed ID: 11753266
[TBL] [Abstract][Full Text] [Related]
6. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
Kharasch ED; Walker A; Hoffer C; Sheffels P
J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.
Kharasch ED; Walker A; Isoherranen N; Hoffer C; Sheffels P; Thummel K; Whittington D; Ensign D
Clin Pharmacol Ther; 2007 Oct; 82(4):410-26. PubMed ID: 17554244
[TBL] [Abstract][Full Text] [Related]
9. Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?
Kharasch ED; Thummel KE
Anesth Analg; 1993 May; 76(5):1033-9. PubMed ID: 8484504
[TBL] [Abstract][Full Text] [Related]
10. Prediction methods of drug-drug interactions of non-oral CYP3A4 substrates based on clinical interaction data after oral administrations - Validation with midazolam, alfentanil, and verapamil after intravenous administration and prediction for blonanserin transdermal patch.
Tomita Y; Yahata M; Hashimoto M; Nishimuta H; Kawaguchi H; Matsushita H; Kitamura A; Nishibe H; Natsui K; Watanabe T
Drug Metab Pharmacokinet; 2020 Aug; 35(4):345-353. PubMed ID: 32660818
[TBL] [Abstract][Full Text] [Related]
11. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting.
Ahonen J; Olkkola KT; Salmenperä M; Hynynen M; Neuvonen PJ
Anesthesiology; 1996 Dec; 85(6):1246-52. PubMed ID: 8968170
[TBL] [Abstract][Full Text] [Related]
12. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study.
Hamaoka N; Oda Y; Hase I; Mizutani K; Nakamoto T; Ishizaki T; Asada A
Clin Pharmacol Ther; 1999 Aug; 66(2):110-7. PubMed ID: 10460064
[TBL] [Abstract][Full Text] [Related]
13. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.
Thummel KE; Shen DD; Podoll TD; Kunze KL; Trager WF; Bacchi CE; Marsh CL; McVicar JP; Barr DM; Perkins JD
J Pharmacol Exp Ther; 1994 Oct; 271(1):557-66. PubMed ID: 7965756
[TBL] [Abstract][Full Text] [Related]
14. Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro.
Oda Y; Mizutani K; Hase I; Nakamoto T; Hamaoka N; Asada A
Br J Anaesth; 1999 Jun; 82(6):900-3. PubMed ID: 10562786
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5.
Klees TM; Sheffels P; Thummel KE; Kharasch ED
Anesthesiology; 2005 Mar; 102(3):550-6. PubMed ID: 15731592
[TBL] [Abstract][Full Text] [Related]
16. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam.
Ibrahim A; Karim A; Feldman J; Kharasch E
Anesth Analg; 2002 Sep; 95(3):667-73, table of contents. PubMed ID: 12198057
[TBL] [Abstract][Full Text] [Related]
17. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
18. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil.
Ibrahim AE; Feldman J; Karim A; Kharasch ED
Anesthesiology; 2003 Apr; 98(4):853-61. PubMed ID: 12657846
[TBL] [Abstract][Full Text] [Related]
20. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
He P; Court MH; Greenblatt DJ; Von Moltke LL
Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]